心脏起搏器联合比索洛尔治疗慢快综合征的疗效

摘要

目的 评价置入永久性心脏起搏器联合比索洛尔治疗慢快综合征患者的疗效.方法 纳入慢快综合征患者45例,均接受永久性心脏起搏器置入并联合比索洛尔治疗,3个月后分析患者临床症状、心电图和超声心动结果对临床疗效进行评价,同时采用SF-36量表对患者生活质量进行评价.结果 经永久性心脏起搏器联合比索洛尔治疗后,所有患者与治疗前相比临床症状减轻,严重心律失常发作频率显著下降(心动过缓:48.89% vs.0;心动过速:33.33% vs.0),心率更加平稳[(65.3±7.2)次/分 vs.(43.5±6.7)次/分],心功能显著改善[NYHA分级:(1.57±0.42) vs.(2.31±0.35)];SF-36量表评分各项指标均有明显改善(P＜0.01).结论 永久性心脏起搏器联合比索洛尔可改善慢快综合征患者预后,提高生活质量.%Objective To review the curative effect of permanent cardiac pacemaker combing bisoprolol on brady—tachy arrhythmia syndrome. Methods The patients ( n=45 ) with brady-tachy arrhythmia syndrome were selected and given the implantation of permanent cardiac pacemaker combing bisoprolol treatment. After 3 months, the curative effect was reviewed through counting and analyzing clinical symptoms and results of electrocardiogram ( ECG ) and echocardiogram. The quality of life in the patients was reviewed by applying SF—36 scale. Results After the treatment, the clinical symptoms were relieved in all patients, seizure frequency of severe arrhythmia decreased significantly ( bradyarrhythmia: 48.89% vs. 0; tachycardia: 33.33% vs. 0 ) , heart rate was more smooth [ ( 65.3 ± 7.2 ) vs. ( 43.5 ± 6.7 ) ], and heart function was significantly improved [NYHA grading: ( 1.57 ± 0.42 ) vs. ( 2.31 ± 0.35 ) ]. The scores of SF-36 scale showed all indexes were significantly improved ( P<0.01 ) . Conclusion Permanent cardiac pacemaker combing bisoprolol can ameliorate the prognosis and improve the quality of life in the patients with brady-tachy arrhythmia syndrome.